Celldex flesh­es out case for Xo­lair chal­lenger in chron­ic hives

Celldex Ther­a­peu­tics is de­tail­ing more da­ta from a Phase I tri­al, close to eight months af­ter shar­ing ini­tial re­spons­es from an in­ter­im analy­sis.

The New Jer­sey biotech rolled out the re­sults at the Amer­i­can Acad­e­my of Al­ler­gy, Asth­ma & Im­munol­o­gy (AAAAI) meet­ing in San An­to­nio on Sun­day, say­ing that it saw a 56% com­plete re­sponse rate af­ter 12 weeks in a Phase Ib tri­al test­ing bar­zolvolimab (for­mer­ly CDX-0159) in pa­tients with mod­er­ate to se­vere chron­ic spon­ta­neous ur­ticaria (CSU) and not re­spond­ing to an­ti­his­t­a­mines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER